[198 Pages Report] The Meningococcal Vaccines Market size was estimated at USD 5.45 billion in 2023 and expected to reach USD 5.95 billion in 2024, at a CAGR 10.50% to reach USD 10.97 billion by 2030.
The FPNV Positioning Matrix is pivotal in evaluating the Meningococcal Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Meningococcal Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
The report delves into recent significant developments in the Meningococcal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Panacea Biotec Ltd., Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Sinovac Biotech Ltd., SK bioscience, Taj Pharmaceuticals Limited, Vabiotech, and Walvax Biotechnology Co., Ltd..
This research report categorizes the Meningococcal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Combination Vaccines
- MenHibrix
- Menitorix
- Conjugate Vaccines
- Menactra
- MenAfriVac
- Meningitec
- Menjugate
- Menveo
- NeisVac-C
- Nimenrix
- NmVac4-DT
- Men B Vaccines
- Bexsero
- Trumenba
- Polysaccharide Vaccines
- Mencevax
- Menomune
- NmVac4
- Combination Vaccines
- Category
- Intramuscular
- Subcutaneous
- Dosage Type
- Booster Vaccination
- Primary Vaccination
- Target Group
- Adult
- Preteen
- Teenager
- End-User
- Hospital Pharmacies
- Pediatric Clinic
- Retail Pharmacies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Meningococcal Vaccines Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Meningococcal Vaccines Market?
- What are the technology trends and regulatory frameworks in the Meningococcal Vaccines Market?
- What is the market share of the leading vendors in the Meningococcal Vaccines Market?
- Which modes and strategic moves are suitable for entering the Meningococcal Vaccines Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Meningococcal Vaccines Market, by Type
- Meningococcal Vaccines Market, by Category
- Meningococcal Vaccines Market, by Dosage Type
- Meningococcal Vaccines Market, by Target Group
- Meningococcal Vaccines Market, by End-User
- Americas Meningococcal Vaccines Market
- Asia-Pacific Meningococcal Vaccines Market
- Europe, Middle East & Africa Meningococcal Vaccines Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 26]
- List of Tables [Total: 830]
- List of Companies Mentioned [Total: 26]
- How big is the Meningococcal Vaccines Market?
- What is the Meningococcal Vaccines Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?